Influence of a PGF2alpha-analogue, etiproston tromethamine, on the functional corpus luteum of dogs.
To induce luteal regression-related abortion/delivery and treat pyometra in dogs, various PGF2alpha-analogues (PGAs) are administered, but a PGA most appropriate for clinical application in dogs, with a low incidence of side effects, is being investigated. In this study, we compared the effects of etiproston tromethamine (PGA-E), which has not been investigated in dogs, with those of cloprostenol (PGA-C), which is routinely used in dogs. A single dose of PGA-E at 100, 200, 400 or 800 microg or PGA-C at 12.5, 25, 50 or 100 microg was administered to beagles (n=5 per group) 25 days after ovulation, when the corpus luteum was in the functional phase. We compared the state of luteal regression by measuring plasma progesterone levels. As side effects, the incidences of salivation, vomiting, tachypnea, diarrhea and the drop in body temperature were investigated. In the 400-microg and 800-microg groups treated with PGA-E, the mean intervals from administration until luteal regression were 18.6 days and 31.2 days, respectively. In the dogs treated with 50 microg or more of PGA-C, luteal regression was noted 2 days after administration. The above side effects were observed for 3 hr after administration of PGA-E/PGA-C. In the dogs treated with 800 microg of PGA-E, the mean body temperature was 36.7 degrees C 4 hr after administration; hypothermia persisted. PGA-E may be less useful than PGA-C for promoting luteal regression in dogs in clinical application.
Kirihara
Nobuyuki
N
Department of Reproduction, Nippon Veterinary and Animal Science University, Kyonan-cho, Musashino-shi, Tokyo, Japan.
Naganawa
Atsuko
A
Hori
Tatsuya
T
Kawakami
Eiichi
E
Tsutsui
Toshihiko
T
D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D003008:Cloprostenol / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects*; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004285:Dogs / Q000097:blood / Q000502:physiology*; D004971:Estrus / Q000187:drug effects*; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood; D003341:Luteolysis / Q000187:drug effects*; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D013997:Time Factors
D003008:Cloprostenol; D011374:Progesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D015237:Dinoprost; C092017:etiproston